Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009975
Filing Date
2025-05-13
Accepted
2025-05-13 16:33:33
Documents
56
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q form10-q.htm   iXBRL 10-Q 636120
2 EX-31.1 ex31-1.htm EX-31.1 13168
3 EX-31.2 ex31-2.htm EX-31.2 13412
4 EX-32.1 ex32-1.htm EX-32.1 9924
  Complete submission text file 0001641172-25-009975.txt   3215718

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE aneb-20250331.xsd EX-101.SCH 23448
6 XBRL CALCULATION FILE aneb-20250331_cal.xml EX-101.CAL 31752
7 XBRL DEFINITION FILE aneb-20250331_def.xml EX-101.DEF 88889
8 XBRL LABEL FILE aneb-20250331_lab.xml EX-101.LAB 245571
9 XBRL PRESENTATION FILE aneb-20250331_pre.xml EX-101.PRE 201754
58 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 321682
Mailing Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734
Business Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

EIN.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-40388 | Film No.: 25940704
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)